D.A. Davidson & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.4M Buy
302,594
+7,665
+3% +$447K 0.11% 146
2025
Q4
$15.9M Buy
294,929
+28,410
+11% +$1.37M 0.1% 161
2025
Q3
$12M Sell
266,519
-78,288
-23% -$3.66M 0.08% 201
2025
Q2
$16M Sell
344,807
-37,438
-10% -$1.84M 0.11% 145
2025
Q1
$23.3M Sell
382,245
-4,032
-1% -$235K 0.19% 94
2024
Q4
$21.8M Buy
386,277
+7,343
+2% +$410K 0.18% 97
2024
Q3
$19.6M Sell
378,934
-36,181
-9% -$1.7M 0.16% 102
2024
Q2
$17.2M Buy
415,115
+37,496
+10% +$1.68M 0.15% 105
2024
Q1
$20.5M Buy
377,619
+79,035
+26% +$4.03M 0.18% 99
2023
Q4
$15.3M Sell
298,584
-22,365
-7% -$1.17M 0.15% 111
2023
Q3
$18.6M Buy
320,949
+11,980
+4% +$734K 0.2% 89
2023
Q2
$19.8M Buy
308,969
+4,262
+1% +$286K 0.21% 88
2023
Q1
$21.1M Buy
304,707
+10,382
+4% +$732K 0.24% 78
2022
Q4
$21.2M Buy
294,325
+4,593
+2% +$346K 0.25% 77
2022
Q3
$20.6M Buy
289,732
+2,458
+0.9% +$178K 0.27% 72
2022
Q2
$22.1M Sell
287,274
-9,307
-3% -$709K 0.28% 70
2022
Q1
$21.7M Sell
296,581
-8,786
-3% -$590K 0.24% 79
2021
Q4
$19M Sell
305,367
-2,828
-0.9% -$166K 0.2% 91
2021
Q3
$18.2M Sell
308,195
-534
-0.2% -$35.2K 0.21% 94
2021
Q2
$20.6M Sell
308,729
-30,074
-9% -$1.96M 0.24% 82
2021
Q1
$21.4M Buy
338,803
+80,518
+31% +$5.01M 0.27% 76
2020
Q4
$16M Sell
258,285
-244
-0.1% -$15K 0.24% 80
2020
Q3
$15.6M Buy
258,529
+14,758
+6% +$888K 0.27% 71
2020
Q2
$14.3M Sell
243,771
-77,301
-24% -$4.62M 0.27% 70
2020
Q1
$17.9M Buy
321,072
+24,904
+8% +$1.52M 0.35% 60
2019
Q4
$19M Buy
296,168
+34,823
+13% +$1.99M 0.31% 65
2019
Q3
$13.3M Buy
261,345
+20,471
+8% +$962K 0.24% 78
2019
Q2
$10.9M Buy
240,874
+9,948
+4% +$463K 0.2% 86
2019
Q1
$11.2M Buy
230,926
+19,915
+9% +$992K 0.19% 93
2018
Q4
$11M Buy
211,011
+3,044
+1% +$164K 0.21% 79
2018
Q3
$12.9M Sell
207,967
-1,519
-0.7% -$90.1K 0.23% 77
2018
Q2
$11.6M Buy
209,486
+5,116
+3% +$276K 0.23% 82
2018
Q1
$12.9M Buy
204,370
+4,073
+2% +$262K 0.27% 71
2017
Q4
$12.3M Sell
200,297
-5,492
-3% -$344K 0.26% 72
2017
Q3
$13.1M Buy
205,789
+16,310
+9% +$952K 0.26% 86
2017
Q2
$10.6M Buy
189,479
+1,092
+0.6% +$59.4K 0.24% 75
2017
Q1
$10.2M Buy
188,387
+18,743
+11% +$1.03M 0.25% 76
2016
Q4
$9.91M Buy
169,644
+15,112
+10% +$826K 0.22% 90
2016
Q3
$8.33M Buy
154,532
+35,002
+29% +$2.25M 0.21% 105
2016
Q2
$8.79M Sell
119,530
-891
-0.7% -$63K 0.26% 79
2016
Q1
$7.69M Buy
120,421
+300
+0.2% +$18.9K 0.24% 89
2015
Q4
$8.26M Buy
120,121
+7,114
+6% +$470K 0.27% 77
2015
Q3
$6.69M Sell
113,007
-1,975
-2% -$125K 0.23% 88
2015
Q2
$7.65M Sell
114,982
-18,006
-14% -$1.19M 0.25% 81
2015
Q1
$8.58M Sell
132,988
-47,034
-26% -$2.94M 0.28% 73
2014
Q4
$10.6M Buy
180,022
+4,563
+3% +$257K 0.35% 62
2014
Q3
$8.98M Sell
175,459
-5,069
-3% -$253K 0.3% 73
2014
Q2
$8.76M Buy
180,528
+9,554
+6% +$471K 0.3% 73
2014
Q1
$8.88M Sell
170,974
-32,607
-16% -$1.74M 0.32% 69
2013
Q4
$10.8M Buy
203,581
+32,092
+19% +$1.63M 0.4% 55
2013
Q3
$7.93M Sell
171,489
-13
-0% -$571 0.36% 67
2013
Q2
$7.66M Buy
+171,502
New +$7.45M 0.37% 65

Other funds holding BMY

D.A. Davidson & Co's BMY Position: Q1 2026 in Review

D.A. Davidson & Co increased its Bristol-Myers Squibb (BMY) stake by 2.6% in Q1 2026, buying an estimated $447K and bringing the position to 302,594 shares worth $18.4M. The position accounts for 0.11% of the portfolio, ranked #146.

D.A. Davidson & Co first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $23.3M in Q1 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • D.A. Davidson & Co held 302,594 shares of Bristol-Myers Squibb worth $18.4M as of Q1 2026.
  • D.A. Davidson & Co bought 7,665 Bristol-Myers Squibb shares in Q1 2026, an estimated $447K.
  • Bristol-Myers Squibb made up 0.11% of D.A. Davidson & Co's portfolio in Q1 2026, its #146 holding.
  • D.A. Davidson & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • D.A. Davidson & Co's Bristol-Myers Squibb position peaked at $23.3M in Q1 2025.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.